Survivin has received great attention due to its expression in many human tumors and its potential as a therapeutic target in cancer. Survivin expression has been described to be cell cycle–dependent and restricted to the G2-M checkpoint, where it inhibits apoptosis in proliferating cells. In agreement with this current view, we found that survivin expression was high in immature neutrophils, which proliferate during differentiation. In contrast with immature cells, mature neutrophils contained only little or no survivin protein. Strikingly, these cells reexpressed survivin upon granulocyte/macrophage colony-stimulating factor (CSF) or granulocyte CSF stimulation in vitro and under inflammatory conditions in vivo. Moreover, survivin-deficient mature neutrophils were unable to increase their lifespan after survival factor exposure. Together, our findings demonstrate the following: (a) overexpression of survivin occurs in primary, even terminally differentiated cells and is not restricted to proliferating cells; and (b) survivin acts as an inhibitor of apoptosis protein in a cell cycle–independent manner. Therefore, survivin plays distinct and independent roles in the maintenance of the G2-M checkpoint and in apoptosis control, and its overexpression is not restricted to proliferating cells. These data provide new insights into the regulation and function of survivin and have important implications for the pathogenesis, diagnosis, and treatment of inflammatory diseases and cancer.
Skip Nav Destination
Article navigation
17 May 2004
Article Contents
Article|
May 17 2004
Inflammation-associated Cell Cycle–independent Block of Apoptosis by Survivin in Terminally Differentiated Neutrophils
Frank Altznauer,
Frank Altznauer
1Department of Pharmacology
Search for other works by this author on:
Sibylla Martinelli,
Sibylla Martinelli
1Department of Pharmacology
Search for other works by this author on:
Christine Thürig,
Christine Thürig
3Institute of Medical Oncology
Search for other works by this author on:
Edward M. Conway,
Edward M. Conway
5Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, B-3000 Leuven, Belgium
Search for other works by this author on:
Martin H. Schöni,
Martin H. Schöni
4Department of Pediatrics, Inselspital, University of Bern, CH-3010 Bern, Switzerl
Search for other works by this author on:
Peter Vogt,
Peter Vogt
6Institute of Clinical Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland
Search for other works by this author on:
Christoph Mueller,
Christoph Mueller
2Department of Pathology
Search for other works by this author on:
Martin F. Fey,
Martin F. Fey
3Institute of Medical Oncology
Search for other works by this author on:
Uwe Zangemeister-Wittke,
Uwe Zangemeister-Wittke
7Department of Oncology, University Hospital Zurich, CH-8044 Zurich, Switzerland
Search for other works by this author on:
Hans-Uwe Simon
Hans-Uwe Simon
1Department of Pharmacology
Search for other works by this author on:
Frank Altznauer
1Department of Pharmacology
Sibylla Martinelli
1Department of Pharmacology
Shida Yousefi
1Department of Pharmacology
Christine Thürig
3Institute of Medical Oncology
Inès Schmid
1Department of Pharmacology
Edward M. Conway
5Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, B-3000 Leuven, Belgium
Martin H. Schöni
4Department of Pediatrics, Inselspital, University of Bern, CH-3010 Bern, Switzerl
Peter Vogt
6Institute of Clinical Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland
Christoph Mueller
2Department of Pathology
Martin F. Fey
3Institute of Medical Oncology
Uwe Zangemeister-Wittke
7Department of Oncology, University Hospital Zurich, CH-8044 Zurich, Switzerland
Hans-Uwe Simon
1Department of Pharmacology
Address correspondence to Hans-Uwe Simon, Dept. of Pharmacology, University of Bern, Friedbühlstrasse 49, CH-3010 Bern, Switzerland. Phone: 41-31-632-3281; Fax: 41-31-632-4992; email: [email protected]
F. Altznauer and S. Martinelli contributed equally to this work.
Abbreviations used in this paper: CF, cystic fibrosis; GAPDH, glyceraldehyde-3–phosphate dehydrogenase; IAP, inhibitor of apoptosis protein; MPO, myeloperoxidase; Smac, second mitochondrial activator of caspase.
Received:
November 25 2003
Accepted:
April 05 2004
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2004
J Exp Med (2004) 199 (10): 1343–1354.
Article history
Received:
November 25 2003
Accepted:
April 05 2004
Citation
Frank Altznauer, Sibylla Martinelli, Shida Yousefi, Christine Thürig, Inès Schmid, Edward M. Conway, Martin H. Schöni, Peter Vogt, Christoph Mueller, Martin F. Fey, Uwe Zangemeister-Wittke, Hans-Uwe Simon; Inflammation-associated Cell Cycle–independent Block of Apoptosis by Survivin in Terminally Differentiated Neutrophils . J Exp Med 17 May 2004; 199 (10): 1343–1354. doi: https://doi.org/10.1084/jem.20032033
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement